The molecular mechanisms and pharmacotherapy of ATP-sensitive potassium channel gene mutations underlying neonatal diabetes

Pharmacogenomics and Personalized Medicine

Volumn 3, Issue 1, 2010, Pages 145-161

  Lang, Veronica ^a   Light, Peter E ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

ABCC8; ATP sensitive potassium channels; KCNJ11; Neonatal diabetes

Indexed keywords

ADENOSINE DIPHOSPHATE; ADENOSINE TRIPHOSPHATE; ADENOSINE TRIPHOSPHATE SENSITIVE POTASSIUM CHANNEL; CHLORPROPAMIDE; CYTOCHROME P450 2C9; GLIBENCLAMIDE; GLICLAZIDE; GLIMEPIRIDE; GLIPIZIDE; GLUCOKINASE; GLUCOSE; INSULIN; INWARDLY RECTIFYING POTASSIUM CHANNEL SUBUNIT KIR6.2; PROTEIN ABCC8; SULFONYLUREA; SULFONYLUREA RECEPTOR; SULFONYLUREA RECEPTOR 1; SULFONYLUREA RECEPTOR 2; TOLAZAMIDE; TOLBUTAMIDE; UNCLASSIFIED DRUG;

ACTIVATION MUTATION; AMINO TERMINAL SEQUENCE; BINDING AFFINITY; BLOOD BRAIN BARRIER; CALCIUM TRANSPORT; CELL MEMBRANE POTENTIAL; CELL MEMBRANE TRANSPORT; CHANNEL GATING; COMBINATION CHEMOTHERAPY; DRUG BINDING SITE; DRUG CLASSIFICATION; DRUG DOSE COMPARISON; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG SELECTIVITY; DRUG STRUCTURE; GENE MUTATION; GENOTYPE PHENOTYPE CORRELATION; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; GLUCOSE METABOLISM; HETEROZYGOSITY; HUMAN; HYPERGLYCEMIA; HYPERINSULINISM; HYPOGLYCEMIA; IC 50; INACTIVATION MUTATION; INSULIN RELEASE; INSULIN SENSITIVITY; INSULIN TREATMENT; JUVENILE DIABETES MELLITUS; LIVER METABOLISM; MONOTHERAPY; NEWBORN DIABETES MELLITUS; NON INSULIN DEPENDENT DIABETES MELLITUS; NUCLEOTIDE BINDING SITE; PANCREAS ISLET BETA CELL; PERMANENT NEONATAL DIABETES MELLITUS; PHARMACOGENOMICS; PHENOTYPE; POTASSIUM CURRENT; PROTEIN DOMAIN; PROTEIN STRUCTURE; PROTEIN VARIANT; REVIEW; SKELETAL MUSCLE; STRUCTURE ACTIVITY RELATION; TRANSIENT NEONATAL DIABETES MELLITUS;

EID: 78650702896     PISSN: None     EISSN: 11787066     Source Type: Book Series    
DOI: 10.2147/PGPM.S6969     Document Type: Review

References (140)

1. Wiedemann B, Schober E, Waldhoer T, et al. Incidence of neonatal diabetes in Austria-calculation based on the Austrian Diabetes Register. Pediatr Diabetes. 2010;11(1):18-23.
2. Slingerland AS, Shields BM, Flanagan SE, et al. Referral rates for diagnostic testing support an incidence of permanent neonatal diabetes in three European countries of at least 1 in 260,000 live births. Diabetologia. 2009;52(8):1683-1685.
3. Hattersley AT, Pearson ER. Minireview: pharmacogenetics and beyond: the interaction of therapeutic response, beta-cell physiology, and genetics in diabetes. Endocrinology. 2006;147(6):2657-2663.
4. Proks P, Antcliff JF, Lippiat J, Gloyn AL, Hattersley AT, Ashcroft FM. Molecular basis of Kir6.2 mutations associated with neonatal diabetes or neonatal diabetes plus neurological features. Proc Natl Acad Sci U S A. 2004;101:17539-17544.
5. Støy J, Edghill EL, Flanagan SE, et al. Insulin gene mutations as a cause of permanent neonatal diabetes. Proc Natl Acad Sci U S A. 2007;104:15040-15044.
6. Colombo C, Porzio O, Liu M, et al. Seven mutations in the human insulin gene linked to permanent neonatal/infancy-onset diabetes mellitus. J Clin Invest. 2008;118:2148-2156.
7. Njølstad PR, Sovik O, Cuesta-Munoz A, et al. Neonatal diabetes mellitus due to complete glucokinase deficiency. N Eng J Med. 2001;344:1588-1592.
8. Njølstad PR, Sagen JV, Bjorkhaug L, et al. Permanent neonatal diabetes caused by glucokinase deficiency: inborn error of the glucose-insulin signaling pathway. Diabetes. 2003;52:2854-2860.
9. Edghill EL, Gloyn AL, Goriely A, et al. Origin of de novo KCNJ11 mutations and risk of neonatal diabetes for subsequent siblings. J Clin Endocrinol Metab. 2007;92:1773-1777.
10. Gloyn AL, Cummings EA, Edghill EL, et al. Permanent neonatal diabetes due to paternal germline mosaicism for an activating mutation of the KCNJ11 gene encoding the Kir6.2 subunit of the beta-cell potassium adenosine triphosphate channel. J Clin Endocrinol Metab. 2004;89:3932-3935.
11. Vaxillaire M, Populaire C, Busiah, K, et al. Kir6.2 mutations are a common cause of permanent neonatal diabetes in a large cohort of French patients. Diabetes. 2004;53:2719-2722.
12. Gloyn AL, Siddiqui J, Ellard S. Mutations in the genes encoding the pancreatic beta-cell KATP channel subunits Kir6.2 (KCNJ11) and SUR1 (ABCC8) in diabetes mellitus and hyperinsulinism. Hum Mutat. 2006;27:220-231.
13. Vaxillaire M, Dechaume A, Busiah K, et al. New ABCC8 mutations in relapsing neonatal diabetes and clinical features. Diabetes. 2007;56:1737-1741.
14. Babenko AP, Polak M, Cave H, et al. Activating mutations in the ABCC8 gene in neonatal diabetes mellitus. N Engl J Med. 2006;355:456-466.
15. Shield JP, Flanagan SE, Mackay DJ, et al. Mosaic paternal uniparental isodisomy and an ABCC8 gene mutation in a patient with permanent neonatal diabetes and hemihypertrophy. Diabetes. 2008;57:255-258.
16. Ashcroft FM, Proks P, Smith PA, et al. Stimulus-secretion coupling in pancreatic p-cells. J Cell Biochem. 1994;55 Suppl:54-65.
17. Proks P, Girard C, Haider S, et al. A gating mutation at the internal mouth of the Kir6.2 pore is associated with DEND syndrome. EMBO Rep. 2005;6:470-475.
18. Ashcroft FM, Rorsman P. Electrophysiology of the pancreatic beta-cell. Prog Biophys Mol Biol. 1989;54:87-143.
19. Cook DL, Hales CN. Intracellular ATP directly blocks K+ channels in pancreatic B-cells. Nature. 1984;311:271-273.
20. Ashcroft FM, Harrison DE, Ashcroft SJ. Glucose induces closure of single potassium channels in isolated rat pancreatic beta-cells. Nature. 1984;312:446-448.
21. Ashcroft FM. ATP-sensitive K channels and disease: from molecule to malady. Am J Physiol Endocrinol Metab. 2007;293:880-889.
22. Ashcroft FM. ATP-sensitive potassium channelopathies: focus on insulin secretion. J Clin Invest. 2005;115:2047-2058.
23. Seino S, Miki T. Physiological and pathophysiological roles of ATPsensitive K+ channels. Prog Biophys Mol Biol. 2003;81:133-176.
24. Miki T, Liss B, Minami K, et al. ATP-sensitive K+ channels in the hypothalamus are essential for the maintenance of glucose homeostasis. Nat Neurosci. 2001;4:507-512.
25. Li DP, Chen SR, Pan HL. Adenosine inhibits paraventricular presympathetic neurons through ATP-dependent potassium channels. J Neurochem. 2010;113(2):530-542.
26. Bahi-Buisson N, Eisermann M, Nivot S, et al. Infantile spasms as an epileptic feature of DEND syndrome associated with an activating mutation in the potassium adenosine triphosphate (ATP) channel, Kir6.2. J Child Neurol. 2007;22(9):1147-1150.
27. Amoroso S, Schmid-Antomarchi H, Fosset M, et al. Glucose, sulfonylureas, and neurotransmitter release: role of ATP-sensitive Ka channels. Science. 1990;247:852-854.
28. Shyng S, Nichols CG. Octameric stoichiometry of the KATP channel complex. J Gen Physiol. 1997;110:655-664.
29. Clement JP, Kunjilwar K, Gonzalez G, et al. Association and stoichiometry of KATP channel subunits. Neuron. 1997;18:827-838.
30. Inagaki N, Gonoi T, Clement JP, et al. Reconstitution of IKATP: an inward rectifier subunit plus the sulfonylurea receptor. Science. 1995;270:1166-1170.
31. Sakura H, Ammala C, Smith PA, et al. Cloning and functional expression of the cDNA encoding a novel ATP-sensitive potassium channel subunit expressed in pancreatic beta-cells, brain, heart and skeletal muscle. FEBS Lett. 1995;377:338-344.
32. Inagaki N, Tsuura Y, Namba N, et al. Cloning and functional characterization of a novel ATP-sensitive potassium channel ubiquitously expressed in rat tissues, including pancreatic islets, pituitary, skeletal muscle, and heart. J Biol Chem. 1995;270:5691-5694.
33. Shi NQ, Ye B, Makielski JC. Function and distribution of the SUR isoforms and splice variants. J Mol Cell Cardiol. 2005;39:51-60.
34. Aguilar-Bryan L, Nichols CG, Wechsler SW, et al. Cloning of the beta cell high-affinity sulfonylurea receptor: a regulator of insulin secretion. Science. 1995;268:423-426.
35. Chutkow WA, Simon MC, Le Beau MM, et al. Cloning, tissue expression, and chromosomal localization of SUR2, the putative drug-binding subunit of cardiac, skeletal muscle, and vascular KATP channels. Diabetes. 1996;45:1439-1445.
36. Isomoto S, Kondo C, Yamada M, et al. A novel sulfonylurea receptor forms with BIR (Kir6.2) a smooth muscle type ATP-sensitive K+ channel. J Biol Chem. 1996;271:24321-24324.
37. Sim JH, Yang DK, Kim YC, et al. ATP-sensitive K+ channels composed of Kir6.1 and SUR2B subunits in guinea pig gastric myocytes. Am J Physiol Gastrointest Liver Physiol. 2002;282:G137-G144.
38. Antcliff JF, Haider S, Proks P, et al. Functional analysis of a structural model of the ATP-binding site of the KATP channel Kir6.2 subunit. EMBO J. 2005;24:229-239.
39. Proks P, Ashcroft FM. Modeling KATP channel gating and its regulation. Prog Biophys Mol Biol. 2009;99:7-19.
40. Masia R, Koster JC, Tumini S, et al. An ATP-binding mutation (G334D) in KCNJ11 is associated with a sulfonylurea-insensitive form of developmental delay, epilepsy, and neonatal diabetes. Diabetes. 2007;56:328-336.
41. Aittoniemi J, Fotinou C, Craig TJ, et al. SUR1: a unique ATP-binding cassette protein that functions as an ion channel regulator. Philos Trans R Soc Lond B Biol Sci. 2009;364(1514):257-267.
42. Miki T, Seino S. Roles of KATP channels as metabolic sensors in acute metabolic changes. J Mol Cell Cardiol. 2005;38:917-925.
43. Nichols CG, Shyng SL, Nestorowicz A, et al. Adenosine diphosphate as an intracellular regulator of insulin secretion. Science. 1996;272:1785-1787.
44. Gribble FM, Tucker SJ, Ashcroft FM. The essential role of the Walker A motifs of SUR1 in K-ATP channel activation by Mg-ADP and diazoxide. EMBO J. 1997;16:1145-1152.
45. Zingman LV, Alekseev AE, Bienengraeber M, et al. Signaling in channel/enzyme multimers: ATPase transitions in SUR module gate ATP-sensitive KAAconductance. Neuron. 2001;31:233-245.
46. Mikhailov MV, Campbell JD, de Wet H, et al. 3-D structural and functional characterization of the purified KATP channel complex Kir6.2-SUR1. EMBO J. 2005;24:4166-4175.
47. Zerangue N, Schwappach B, Jan YN, et al. A new ER trafficking signal regulates the subunit stoichiometry of plasma membrane KATP channels. Neuron. 1999;22:537-548.
48. Bienengraeber M, Alekseev AE, Abraham MR, et al. ATPase activity of the sulfonylurea receptor: a catalytic function for the KATP channel complex. FASEB J. 2000;14:1943-1952.
49. Thomas PM, Ye Y, Lightner E. Mutation of the pancreatic islet inward rectifier Kir6.2 also leads to familial persistent hyperinsulinemic hypoglycemia of infancy. Hum Mol Genet. 1996;5:1809-1812.
50. Thomas PM, Cote GJ, Wohllk N, et al. Mutations in the sulfonylurea receptor gene in familial persistent hyperinsulinemic hypoglycemia of infancy. Science. 1995;268:426-429.
51. Gloyn AL, Pearson ER, Antcliff J, et al. Activating mutations in the gene encoding the ATP sensitive potassium-channel subunit Kir6.2 and permanent neonatal diabetes. N Eng J Med. 2004;350:1838-1849.
52. Colombo C, Delvecchio M, Zecchino C, et al. Transient neonatal diabetes mellitus is associated with a recurrent (R201H) KCNJ11 (KIR6.2) mutation. Diabetologia. 2005;48(11):2439-2441.
53. Yorifuji T, Nagashima K, Kurokawa K, et al. The C42R mutation in the Kir6.2 (KCNJ11) gene as a cause of transient neonatal diabetes, childhood diabetes, or later-onset, apparently type 2 diabetes mellitus. J Clin Endocrinol Metab. 2005;90(6):3174-3178.
54. Riedel MJ, Steckley DC, Light PE. Current status of the E23K Kir6.2 polymorphism: implications for type-2 diabetes. Hum Genet. 2005;116(3):133-145.
55. Tarasov AI, Nicolson TJ, Riveline JP, et al. A rare mutation in ABCC8/ SUR1 leading to altered ATP-sensitive KSSchannel activity and beta-cell glucose sensing is associated with type 2 diabetes in adults. Diabetes. 2008;57(6):1595-1604.
56. Dunne MJ, Cosgrove KE, Shepherd RM, et al. Hyperinsulinism in infancy: from basic science to clinical disease. Physiol Rev. 2004;84:239-275.
57. Dunne MJ, Kane C, Shepherd RM, et al. Familial persistent hyperinsulinemic hypoglycemia of infancy and mutations in the sulfonylurea receptor. N Engl J Med. 1997;336(10):703-706.
58. Shimomura K, Flanagan SE, Zadek B, et al. Adjacent mutations in the gating loop of Kir6.2 produce neonatal diabetes and hyperinsulinism. EMBO Mol Med. 2009;1:166-177.
59. Glaser B, Thornton P, Otonkoski T, et al. Genetics of neonatal hyperinsulinism. Arch Dis Child. 2000;82:F79-F86.
60. Flanagan SE, Clauin S, Bellanne-Chantelot C, et al. Update of mutations in the genes encoding the pancreatic beta-cell K(ATP) channel subunits Kir6.2 (KCNJ11) and sulfonylurea receptor 1 (ABCC8) in diabetes mellitus and hyperinsulinism. Hum Mutat. 2009;30:170-180.
61. Taschenberger G, Mougey A, Shen S, et al. Identification of a familial hyperinsulinism causing mutation in the sulfonylurea receptor 1 that prevents normal trafficking and function of KATP channels. J Biol Chem. 2002;277:17139-17146.
62. Partridge CJ, Beech DJ, Sivaprasadarao A. Identification and pharmacological correction of a membrane trafficking defect associated with a mutation in the sulfonylurea receptor causing familial hyperinsulinism. J Biol Chem. 2001;276:35947-35952.
63. Yan F, Lin CW, Weisiger E, et al. Sulfonylureas correct trafficking defects of ATP-sensitive potassium channels caused by mutations in the sulfonylurea receptor. J Biol Chem. 2004;279:11096-11105.
64. Huopio H, Reimann F, Ashfield R, et al. Dominantly inherited hyperinsulinism caused by a mutation in the sulfonylurea receptor type 1. J Clin Invest. 2000;106:897-906.
65. Matsuo M, Trapp S, Tanizawa Y, et al. Functional analysis of a mutant sulfonylurea receptor, SUR1-R1420C, that is responsible for persistent hyperinsulinemic hypoglycemia of infancy. J Biol Chem. 2000;275:41184-41191.
66. Shyng SL, Ferrigni T, Shepard JB, et al. Functional analyses of novel mutations in the sulfonylurea receptor 1 associated with persistent hyperinsulinemic hypoglycemia of infancy. Diabetes. 1998;47:1145-1151.
67. Pinney SE, MacMullen C, Becker S, et al. Clinical characteristics and biochemical mechanisms of congenital hyperinsulinism associated with dominant KATP channel mutations. J Clin Invest. 2008;118:2877-2886.
68. Amato ED, Tammaro P, Craig TJ, et al. Variable phenotypic spectrum of diabetes mellitus in a family carrying a novel KCNJ11 gene mutation. Diabet Med. 2008;25:651-656.
69. Shimomura K, Girard CA, Proks P, et al. Mutations at the same residue (R50) of Kir6.2 (KCNJ11) that cause neonatal diabetes produce different functional effects. Diabetes. 2006;55:1705-1712.
70. Girard C, Shimomura K, Proks P, et al. Functional analysis of six Kir6.2 (KCNJ11) mutations causing neonatal diabetes. Pflugers Arch. 2006;453:323-332.
71. Tarasov AI, Girard CA, Larkin B, et al. Functional analysis of two Kir6.2 (KCNJ11) mutat ions, K170T and E322K, causing neonatal diabetes. Diabetes Obes Metab. 2007;9 Suppl 2:46-55.
72. Klupa T, Edghill EL, Nazim J, et al. The identification of a R201H mutation in KCNJ11, which encodes Kir6.2, and successful transfer to sustained-release sulphonylurea therapy in a subject with neonatal diabetes: evidence for heterogeneity of beta cell function among carriers of the R201H mutation. Diabetologia. 2005;48:1029-1031.
73. Flanagan SE, Edghill EL, Gloyn AL, et al. Mutations in KCNJ11, which encodes Kir6.2, are a common cause of diabetes diagnosed in the first 6 months of life, with the phenotype determined by genotype. Diabetologia. 2006;49:1190-1197.
74. Flanagan SE, Patch AM, Mackay DJ, et al. Mutations in ATP-sensitive K+ channel genes cause transient neonatal diabetes and permanent diabetes in childhood or adulthood. Diabetes. 2007;56:1930-1937.
75. Slingerland AS, Hurkx W, Noordam K, et al. Sulphonylurea therapy improves cognition in a patient with the V59M KCNJ11 mutation. Diabet Med. 2008;25:277-281.
76. Doyle DA, Morais Cabral J, Pfuetzner RA, et al. The structure of the potassium channel: molecular basis of Kppconduction and selectivity. Science. 1998;280:69-77.
77. Hattersley AT, Ashcroft FM. Activating mutations in Kir6.2 and neonatal diabetes: new clinical syndromes, new scientific insights, and new therapy. Diabetes. 2005;54:2503-2513.
78. Proks P, Girard C, Baevre H, et al. Functional effects of mutations at F35 in the NH2-terminus of Kir6.2 (KCNJ11), causing neonatal diabetes, and response to sulfonylurea therapy. Diabetes. 2006;55(6):1731-1737.
79. Reimann F, Tucker SJ, Proks P, et al. Involvement of the N-terminus of Kir6.2 in coupling to the sulphonylurea receptor. J Physiol. 1999;518:325-336.
80. Babenko AP, Bryan J. SUR-dependent modulation of KATP channels by an N-terminal Kir6.2 peptide: defining intersubunit gating interactions. J Biol Chem. 2002;277:43997-44004.
81. Koster JC, Kurata HT, Enkvetchakul D, et al. A DEND mutation in Kir6.2 (KCNJ11) reveals a flexible N-terminal region critical for ATP- sensing of the KATP channel. Biophys J. 2008;95:4689-4697.
82. Proks P, Girard C, Ashcroft FM. Functional effects of KCNJ11 mutations causing neonatal diabetes: enhanced activation by Mg-ATP. Hum Mol Genet. 2005;14:2717-2726.
83. Tarasov AI, Welters HJ, Senkel S, et al. A Kir6.2 mutation causing neonatal diabetes impairs electrical activity and insulin secretion from INS-1 beta-cells. Diabetes. 2006;55:3075-3082.
84. Männikkö R, Jefferies C, Flanagan SE, et al. Interaction between mutations in the slide helix of Kir6.2 associated with neonatal diabetes and neurological symptoms. Hum Mol Genet. 2010;19(6):963-972.
85. Gloyn AL, Reimann F, Girard C, et al. Relapsing diabetes can result from moderately activating mutations in KCNJ11. Hum Mol Genet. 2005;14:925-934.
86. John SA, Weiss JN, Xie LH, et al. Molecular mechanism for ATPdependent closure of the Kccchannel Kir6.2. J Physiol. 2003;552:23-34.
87. Proks P, Arnold AL, Bruining J, et al. A heterozygous activating mutation in the sulphonylurea receptor SUR1 (ABCC8) causes neonatal diabetes. Hum Mol Genet. 2006;15:1793-1800.
88. Proks P, Shimomura K, Craig TJ, et al. Mechanism of action of a sulphonylurea receptor SUR1 mutation (F132L) that causes DEND syndrome. Hum Mol Genet. 2007;16:2011-2019.
89. Fang K, Csanady L, Cha KW. The N-terminal transmembrane domain (TMD0) and a cytosolic linker (L0) of sulphonylurea receptor define the unique intrinsic gating of KATP channels. J Physiol. 2006;576:379-389.
90. Masia R, de Leon DD, MacMullen C, et al. A mutation in the TMD0-L0 region of sulfonylurea receptor-1 (L225P) causes permanent neonatal diabetes mellitus (PNDM). Diabetes. 2007;56:1357-1362.
91. Patch AM, Flanagan SE, Boustred C, et al. Mutations in the ABCC8 gene encoding the SUR1 subunit of the KATP channel cause transient neonatal diabetes, permanent neonatal diabetes or permanent diabetes diagnosed outside the neonatal period. Diabetes Obes Metab. 2007;9 Suppl 2:28-39.
92. Babenko AP, Bryan J. SUR domains that associate with and gate KATP pores define a novel gatekeeper. J Biol Chem. 2003;278:41577-41580.
93. Tammaro P, Girard C, Molnes J, et al. Kir6.2 mutations causing neonatal diabetes provide new insights into Kir6.2-SUR1 interactions. EMBO J. 2005;24:2318-2330.
94. de Wet H, Rees MG, Shimomura K, et al. Increased ATPase activity produced by mutations at arginine-1380 in nucleotide-binding domain 2 of ABCC8 causes neonatal diabetes. Proc Natl Acad Sci U S A. 2007;104:18988-18992.
95. de Wet H, Proks P, Lafond M, et al. A mutation (R826 W) in nucleotide- binding domain 1 of ABCC8 reduces ATPase activity and causes transient neonatal diabetes. EMBO Rep. 2008;9:648-654.
96. Ellard S, Flanagan SE, Girard CA, et al. Permanent neonatal diabetes caused by dominant, recessive, or compound heterozygous SUR1 mutations with opposite functional effects. Am J Hum Genet. 2007;81:375-382.
97. Markworth E, Schwanstecher C, Schwanstecher M. ATP4-mediates closure of pancreatic beta-cell ATP-sensitive potassium channels by interaction with 1 of 4 identical sites. Diabetes. 2000;49:1413-1418.
98. Hani EH, Boutin P, Durand E, et al. Missense mutations in the pancreatic islet beta cell inwardly rectifying Kiichannel gene (KIR6.2/ BIR): a meta-analysis suggests a role in the polygenic basis of type II diabetes mellitus in Caucasians. Diabetologia. 1998;41:1511-1515.
99. Gloyn AL, Weedon MN, Owen KR, et al. Large-scale association studies of variants in genes encoding the pancreatic beta-cell KATP channel subunits Kir6.2 (KCNJ11) and SUR1 (ABCC8) confirm that the KCNJ11 E23K variant is associated with type 2 diabetes. Diabetes. 2003;52:568-572.
100. Barroso I, Luan J, Middelberg RP, et al. Candidate gene association study in type 2 diabetes indicates a role for genes involved in beta-cell function as well as insulin action. PLoS Biol. 2003;1:E20.
101. Hamming KS, Soliman D, Matemisz LC, et al. Coexpression of the type 2 diabetes susceptibility gene variants KCNJ11 E23K and ABCC8 S1369A alter the ATP and sulfonylurea sensitivities of the ATP-sensitive K channel. Diabetes. 2009;58:2419-2424.
102. Sperling MA. Neonatal diabetes mellitus: from understudy to center stage. Curr Opin Pediatr. 2005;17(4):512-518.
103. Polak M, Shield J. Neonatal and very-early-onset diabetes mellitus. Semin Neonatol. 2004;9:59-65.
104. Greeley SA, Tucker SE, Worrell HI, et al. Update in neonatal diabetes. Curr Opin Endocrinol Diabetes Obes. 2010;17(1):13-19.
105. Sagen JV, Raeder H, Hathout E, et al. Permanent neonatal diabetes due to mutations in KCNJ11 encoding Kir6.2: patient characteristics and initial response to sulfonylurea therapy. Diabetes. 2004;53:2713-2718.
106. Stanik J, Gasperikova D, Paskova M, et al. Prevalence of permanent neonatal diabetes in Slovakia and successful replacement of insulin with sulfonylurea therapy in KCNJ11 and ABCC8 mutation carriers. J Clin Endocrinol Metab. 2007;92:1276-1282.
107. UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837-853.
108. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Eng J Med. 1993;329:977-986.
109. Winkler M, Stephan D, Bieger S, et al. Testing the bipartite model of the sulfonylurea receptor binding site: binding of A-, B-, and A B-site ligands. J Pharmacol Exp Ther. 2007;322:701-708.
110. Ashcroft FM. New uses for old drugs: neonatal diabetes and sulphonylureas. Cell Metab. 2010;11:179-181.
111. Stoy J, Greeley SA, Paz VP, et al. Diagnosis and treatment of neonatal diabetes: an United States experience. Pediatr Diabetes. 2008;9:450-459.
112. Proks P, Reimann F, Green N, et al. Sulfonylurea stimulation of insulin secretion. Diabetes. 2002;51 Suppl 3:S368-S376.
113. Zung A, Glaser B, Nimri R, et al. Glibenclamide treatment in permanent neonatal diabetes mellitus due to an activating mutation in Kir6.2. J Clin Endocrinol Metab. 2004;89:5504-5507.
114. Manna TD, Battistim C, Radonsky V, et al. Glibenclamide unresponsiveness in a brazilian child with permanent neonatal diabetes mellitus and DEND syndrome due to a C166Y mutation in KCNJ11 (Kir6.2) gene. Arq Bras Endocrinol Metabol. 2008;52(8):1350-1355.
115. Koster JC, Remedi MS, Dao C, et al. ATP and sulfonylurea sensitivity of mutant ATP-sensitive K channels in neonatal diabetes: implications for pharmacogenomic therapy. Diabetes. 2005;54:2645-2654.
116. Pearson ER, Flechtner I, Njolstad PR, et al. Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir6.2 mutations. N Eng J Med. 2006;355:467-477.
117. Chen K, Wang R, Wen SY, et al. Relationship of P450 2C9 genetic polymorphisms in Chinese and the pharmacokinetics of tolbutamide. J Clin Pharm Ther. 2005;30(3):241-249.
118. Kirchheiner J, Roots I, Goldammer M, et al. Effect of genetic polymorphisms in cytochrome p450 (CYP) 2C9 and CYP2C8 on the pharmacokinetics of oral antidiabetic drugs: clinical relevance. Clin Pharmacokinet. 2005;44(12):1209-1225.
119. Suzuki K, Yanagawa T, Shibasaki T, et al. Effect of CYP2C9 genetic polymorphisms on the efficacy and pharmacokinetics of glimepiride in subjects with type 2 diabetes. Diabetes Res Clin Pract. 2006;72(2):148-154.
120. Becker ML, Visser LE, Trienekens PH, et al. Cytochrome P450 2C9 *2 and *3 polymorphisms and the dose and effect of sulfonylurea in type II diabetes mellitus. Clin Pharmacol Ther. 2008;83(2):288-292.
121. Slingerland AS, Nuboer R, Hadders-Algra M, et al. Improved motor development and good long-term glycemic control with sulfonylurea treatment in a patient with the syndrome of intermediate developmental delay, early-onset generalised epilepsy and neonatal diabetes associated with the V59M mutation in the KCNJ11 gene. Diabetologia. 2006;49:2559-2563.
122. Mlynarski W, Tarasov A, Gach A, et al. Sulfonylurea improves CNS function in a case of intermediate DEND syndrome caused by a mutation in KCNJ11. Nat Clin Pract Neurol. 2007;3(11):640-645.
123. Koster JC, Cadario F, Peruzzi C, et al. The G53D mutation in Kir6.2 (KCNJ11) is associated with neonatal diabetes and motor dysfunction in adulthood that is improved with sulfonylurea therapy. J Clin Endocrinol Metab. 2008;93:1054-1061.
124. Turkkahraman D, Bircan I, Tribble ND, et al. Permanent neonatal diabetes mellitus caused by a novel homozygous (T168A) glucokinase (GCK) mutation: initial response to oral sulphonylurea therapy. J Pediatr. 2008;153:122-126.
125. Søvik O, Njølstad P, Følling I, et al. Hyperexcitability to sulphonylurea in MODY3. Diabetologia. 1998;41(5):607-608.
126. Pearson ER, Liddell WG, Shepherd M, et al. Sensitivity to sulphonylureas in patients with hepatocyte nuclear factor-1 alpha gene mutations: evidence for pharmacogenetics in diabetes. Diabet Med. 2000;17(7):543-545.
127. Gribble FM, Reimann F. Differential selectivity of insulin secretagogues mechanisms, clinical implications, and drug interactions. J Diabetes Complications. 2003;17 Suppl 2:11-15.
128. Gribble FM, Reimann F. Sulphonylurea action revisited: the postcloning era. Diabetologia. 2003;46:875-891.
129. Inagaki N, Gonoi T, Clement JP, et al. A family of sulfonylurea receptors determines the pharmacological properties of ATP-sensitive K+ channels. Neuron. 1996;16:1011-1017.
130. Gribble FM, Tucker SJ, Seino S, et al. Tissue specificity of sulfonylureas: studies on cloned cardiac and beta-cell K(ATP) channels. Diabetes. 1998;47(9):1412-1418.
131. Gribble FM, Ashcroft FM. Differential sensitivity of beta-cell and extrapancreatic K(ATP) channels to gliclazide. Diabetologia. 1999;42(7):845-848.
132. Song DK, Ashcroft FM. Glimepiride block of cloned beta-cell, cardiac and smooth muscle K(ATP) channels. Br J Pharmacol. 2001;133(1):193-199.
133. Miki T, Minami K, Zhang L, et al. ATP-sensitive potassium channels participate in glucose uptake in skeletal muscle and adipose tissue. Am J Physiol Endocrinol Metab. 2002;283:E1178-E1184.
134. Chutkow WA, Samuel V, Hansen PA, et al. Disruption of SUR2- containing K(ATP) channels enhances insulin-stimulated glucose uptake in skeletal muscle. Proc Natl Acad Sci U S A. 2001;98:11760-11764.
135. Skupien J, Malecki MT, Mlynarski W, et al. Assessment of insulin sensitivity in adults with permanent neonatal diabetes mellitus due to mutations in the KCNJ11 gene encoding Kir6.2. Rev Diabet Stud. 2006;3(1):17-20.
136. Malecki MT, Skupien J, Klupa T, et al. Transfer to sulphonylurea therapy in adult subjects with permanent neonatal diabetes due to KCNJ11-activating mutations: evidence for improvement in insulin sensitivity. Diabetes Care. 2007;30(1):147-149.
137. Tessier D, Dawson K, Tétrault JP, et al. Glibenclamide vs gliclazide in type 2 diabetes of the elderly. Diabet Med. 1994;11(10):974-980.
138. Hattersley A, Bruining J, Shield J, et al. ISPAD Clinical Practice Consensus Guidelines 2006-2007. The diagnosis and management of monogenic diabetes in children. Pediatr Diabetes. 2006;7(6):352-360.
139. Pun P, Clark R, Wan KW, et al. Neonatal diabetes mellitus: the impact of molecular diagnosis. NeoReviews. 2010;11(6):e306-e310.
140. DiStefano JK, Watanabe RM. Pharmacogenetics of anti-diabetes drugs. Pharmaceuticals. 2010;3(8):2610-2646.